文献速递头颈与中枢神经肿瘤

联合细胞毒与免疫刺激基因治疗用于原发性成人高级别胶质瘤:一项1期首次人体试验

Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

这项1期首次人体剂量探索试验在18例初治成人高级别胶质瘤患者中评估了表达HSV1-TK和Flt3L的两种腺病毒载体联合治疗的安全性和活性。最大耐受剂量未达到,未观察到剂量限制性毒性,中位总生存期为21.3个月(95%CI 11.1-26.1)。作者认为该联合方案安全可行,值得进一步开展1b/2期临床试验。

要点

  • 最大耐受剂量未达到,未观察到剂量限制性毒性。
  • 最常见3-4级严重不良事件为伤口感染(2例患者共4次事件)和血栓栓塞事件(4例患者共5次事件)。
  • 中位总生存期为21.3个月(95%CI 11.1-26.1)。

核心结论

  • 两种腺病毒载体联合方案在高级别胶质瘤患者中显示出安全性和可行性,值得进一步开展1b/2期临床试验。

研究设计与样本

  • 这是一项剂量探索的首次人体试验,采用3+3设计,共设6个病毒颗粒剂量递增队列(队列A至F)。
  • 研究纳入18例年龄18-75岁、新诊断高级别胶质瘤、Karnofsky体能状态评分70分以上的初治成人患者,每个剂量队列3例。
  • 患者接受最大安全切除后,向瘤床注射表达HSV1-TK的Ad-hCMV-TK和表达Flt3L的Ad-hCMV-Flt3L腺病毒载体,随后接受两个14天疗程的伐昔洛韦(2 g口服,每日三次)及标准 upfront 放化疗。
  • 研究在密歇根大学医学院Michigan Medicine(美国密歇根州安娜堡)进行。
  • 主要终点为Ad-hCMV-Flt3L和Ad-hCMV-TK的最大耐受剂量,总生存期为次要终点。

主要发现

  • 2014年4月8日至2019年3月13日期间,21例患者接受资格评估,18例高级别胶质瘤患者入组并纳入分析(6个剂量队列各3例);8例女性,10例男性。
  • 神经病理学检查显示14例(78%)为胶质母细胞瘤,3例(17%)为胶质肉瘤,1例(6%)为间变性室管膜瘤。
  • 治疗耐受良好,未观察到剂量限制性毒性,最大耐受剂量未达到。
  • 所有治疗组中最常见的3-4级严重不良事件为伤口感染(2例患者共4次事件)和血栓栓塞事件(4例患者共5次事件)。
  • 发生1例不良事件导致的死亡(呼吸衰竭),但与研究治疗无关;研究期间无治疗相关死亡。

关键数值与推荐

  • 病毒颗粒剂量递增方案:队列A为1×10^10 Ad-hCMV-TK病毒颗粒和1×10^9 Ad-hCMV-Flt3L病毒颗粒;队列B为1×10^11 Ad-hCMV-TK和1×10^9 Ad-hCMV-Flt3L;队列C为1×10^10 Ad-hCMV-TK和1×10^10 Ad-hCMV-Flt3L;队列D为1×10^11 Ad-hCMV-TK和1×10^10 Ad-hCMV-Flt3L;队列E为1×10^10 Ad-hCMV-TK和1×10^11 Ad-hCMV-Flt3L;队列F为1×10^11 Ad-hCMV-TK和1×10^11 Ad-hCMV-Flt3L。
  • 给药方式为使用两支1 mL结核菌素注射器徒手将Ad-hCMV-TK和Ad-hCMV-Flt3L载体混合液注入切除腔壁,总注射量2 mL,分20个位点、每位点0.1 mL。
  • 伐昔洛韦用法为2 g口服、每日三次,于载体给药后1-3天和10-12周各给予一个14天疗程。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade gliomas have a poor prognosis and do not respond well to treatment. Effective cancer immune responses depend on functional immune cells, which are typically absent from the brain. This study aimed to evaluate the safety and activity of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in patients with high-grade glioma. METHODS: In this dose-finding, first-in-human trial, treatment-naive adults aged 18-75 years with newly identified high-grade glioma that was evaluated per immunotherapy response assessment in neuro-oncology criteria, and a Karnofsky Performance Status score of 70 or more, underwent maximal safe resection followed by injections of adenoviral vectors expressing HSV1-TK and Flt3L into the tumour bed. The study was conducted at the University of Michigan Medical School, Michigan Medicine (Ann Arbor, MI, USA). The study included six escalating doses of viral particles with starting doses of 1×1010 Ad-hCMV-TK viral particles and 1×109 Ad-hCMV-Flt3L viral particles (cohort A), and then 1×1011 Ad-hCMV-TK viral particles and 1×109 Ad-hCMV-Flt3L viral particles (cohort B), 1×1010 Ad-hCMV-TK viral particles and 1×1010 Ad-hCMV-Flt3L viral particles (cohort C), 1×1011 Ad-hCMV-TK viral particles and 1×1010 Ad-hCMV-Flt3L viral particles (cohort D), 1×1010 Ad-hCMV-TK viral particles and 1×1011 Ad-hCMV-Flt3L viral particles (cohort E), and 1×1011 Ad-hCMV-TK viral particles and 1×1011 Ad-hCMV-Flt3L viral particles (cohort F) following a 3+3 design. Two 1 mL tuberculin syringes were used to deliver freehand a mix of Ad-hCMV-TK and Ad-hCMV-Flt3L vectors into the walls of the resection cavity with a total injection of 2 mL distributed as 0·1 mL per site across 20 locations. Subsequently, patients received two 14-day courses of valacyclovir (2 g orally, three times per day) at 1-3 days and 10-12 weeks after vector administration and standad upfront chemoradiotherapy. The primary endpoint was the maximum tolerated dose of Ad-hCMV-Flt3L and Ad-hCMV-TK. Overall survival was a secondary endpoint. Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT01811992. FINDINGS: Between April 8, 2014, and March 13, 2019, 21 patients were assessed for eligibility and 18 patients with high-grade glioma were enrolled and included in the analysis (three patients in each of the six dose cohorts); eight patients were female and ten were male. Neuropathological examination identified 14 (78%) patients with glioblastoma, three (17%) with gliosarcoma, and one (6%) with anaplastic ependymoma. The treatment was well-tolerated, and no dose-limiting toxicity was observed. The maximum tolerated dose was not reached. The most common serious grade 3-4 adverse events across all treatment groups were wound infection (four events in two patients) and thromboembolic events (five events in four patients). One death due to an adverse event (respiratory failure) occurred but was not related to study treatment. No treatment-related deaths occurred during the study. Median overall survival was 21·3 months (95% CI 11·1-26·1). INTERPRETATION: The combination of two adenoviral vectors demonstrated safety and feasibility in patients with high-grade glioma and warrants further investigation in a phase 1b/2 clinical trial. FUNDING: Funded in part by Phase One Foundation, Los Angeles, CA, The Board of Governors at Cedars-Sinai Medical Center, Los Angeles, CA, and The Rogel Cancer Center at The University of Michigan.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Umemura Y, Orringer D, Junck L, et al. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial. Lancet Oncol. 2023. PMID: 37657463. doi:10.1016/S1470-2045(23)00347-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。